R9156

Raltitrexed

≥98% (HPLC), solid

• Synonym(e): L-Glutamic acid, N-((5-(((1,4-dihydro-2-methyl-4-oxo-6-quinazolinyl)methyl)methylamino)-2-thienyl)carbonyl), ICI-D-1694, ZD-1694
• Empirische Formel (Hill-System): C₂₁H₂₂N₄O₆S
• CAS-Nummer: 112887-68-0
• Molekulargewicht: 458.49
• UNSPSC-Code: 12352200
• PubChem Substanz-ID: 329824044
• NACRES: NA.77

Eigenschaften

• Assay: ≥98% (HPLC)
• Form: solid
• Farbe: off-white to light yellow
• Löslichkeit: H₂O: ≥10 mg/mL; DMSO: ≥40 mg/mL
• Ersteller: AstraZeneca
• Lagertemp.: 2-8°C
• SMILES String: O=C1NC(C)=NC2=C1C=C(CN(C3=CC=C(C(N[C@H](CCC(O)=O)C(O)=O)=O)S3)C)C=C2

Beschreibung

Biochem./physiol. Wirkung

Raltitrexed is a folate-based inhibitor of thymidylate synthase (TS) that is rapidly and extensively metabolized to its more potent polyglutamate derivatives.

Raltitrexed is a folate-based inhibitor of thymidylate synthase (TS) that is rapidly and extensively metabolized to its more potent polyglutamate derivatives. By inhibiting the formation of precursor pyrimidine nucleotides, raltitrexed prevents the formation of DNA and RNA, which are required for the growth and survival of both normal cells and cancer cells.

Leistungsmerkmale und Vorteile

This compound is a featured product for Apoptosis research. Click here to discover more featured Apoptosis products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.

This compound was developed by AstraZeneca. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Sicherheitshinweise

• Piktogramme: GHS06,GHS08
• Signalwort: Danger
• H-Sätze: H300,H360
• P-Sätze: P201 - P301 + P310 + P330
• Gefahreneinstufungen: Acute Tox. 2 Oral - Repr. 1B
• Lagerklassenschlüssel: 6.1A - Combustible acute toxic Cat. 1 and 2 / very toxic hazardous materials
• WGK: WGK 2
• Flammpunkt (°F): Not applicable
• Flammpunkt (°C): Not applicable
• Persönliche Schutzausrüstung: Eyeshields, Faceshields, Gloves, type P2 (EN 143) respirator cartridges